Open access journal · Editorial and peer review
Lexfolio Journal of Law, Policy and Social Sciences
- LJLPS
- Published by Lexfolio, India
- Bi-monthly, rolling publication
- Online ISSN: applied for after Volume 1, Issue 1
Lexfolio/LJLPS/TRIPS Flexibilities and Institutional Capacity: Rethinking Intellectual Property and Development in Developing Countries
TRIPS Flexibilities and Institutional Capacity: Rethinking Intellectual Property and Development in Developing Countries
Arguments over the WTO Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) tend to fall into two camps. One holds that stronger property rights naturally draw in technological investment; the other, that multilateral patent standards inevitably choke social development in low-income economies. This article argues that both camps overlook how legal rights interact with the institutions that must carry them out. It proposes a model in which the developmental return from TRIPS depends on three things working together: legal policy space, administrative state capacity and domestic productive capability. Legal policy space is what a sovereign state may do under its treaty obligations and domestic law. Administrative capacity is whether public bodies (patent examiners, medicine regulators, procurement offices and appellate courts) have the technical resources, procedural clarity and independence to frame, apply and defend those measures. Productive capability is whether local manufacturers, laboratories and distribution systems can absorb outside knowledge and put quality-assured goods in people’s hands.Drawing on doctrinal analysis of TRIPS, the 2001 Doha Declaration, key WTO dispute reports and the patent practice of India, Thailand and Brazil, the article shows why statutory flexibilities so often fail where public administration is fragile or manufacturing is weak. It closes with an implementation agenda that ties intellectual property administration to industrial policy, public health infrastructure and administrative reform.
Keywords: TRIPS Agreement; compulsory licensing; section 3(d); Doha Declaration; technology transfer; Article 31bis; institutional capacity; absorptive capability
1. Introduction
When TRIPS1 was adopted in 1994, intellectual property stopped being a field in which each state exercised its own discretion under the older conventions. It became a binding multilateral obligation, backed by compulsory dispute settlement and the threat of cross-retaliatory trade sanctions.2 Three decades on, the scholarship and the diplomacy surrounding that shift have settled into two entrenched positions.
The first, the orthodox trade view, has long been associated with capital-exporting economies and research-based pharmaceutical companies. It treats harmonised rules as a precondition for economic modernisation.3 Patents, on this account, drive growth: they encourage private research spending, attract inbound foreign direct investment (FDI) and promote cross-border licensing of advanced industrial technology. High prices and limited access to essential medicines in developing countries are read as short-term market adjustments, or as failures of domestic distribution, rather than defects in the intellectual property regime itself.
The second position comes from critical legal scholarship, health advocates and developing-country coalitions, who see TRIPS as an instrument of regulatory capture.4 They point out that developing countries accepted the Agreement in the Uruguay Round as part of a contested bargain: binding protection for foreign intellectual property was traded for commitments on agricultural market access and textile quotas that were slow to materialise.5 For these critics, TRIPS creates artificial scarcity in public goods, moves economic rents from resource-constrained countries to foreign rights holders, limits reverse engineering, and endangers public health by raising the price of life-saving drugs.6
For all their differences, the two sides share a habit that might be called institutional reductionism: each treats formal legal provisions as the main determinant of real-world outcomes. The orthodox view assumes that a twenty-year patent term will, by itself, bring in venture capital and create local manufacturing. The critical view often assumes that writing exceptions into a statute, or issuing a compulsory licence, will quickly produce plentiful cheap medicines. Neither assumption survives contact with the evidence. What intellectual property standards actually do for development depends heavily on the administrative and industrial institutions of the country concerned.
The model developed here has three parts: legal policy space, administrative state capacity and domestic productive capability. Put briefly, the first is what treaty law lets a Member do, the second is whether its public institutions can actually do it, and the third is whether its industry can supply what follows. A country may have a well-drafted compulsory licensing provision and still fail to bring down the cost of treatment if its health system has no bioequivalence testing facilities, no domestic formulation plants and no competent public tendering.
Section 2 sets out the minimum-standards structure of TRIPS and the discretion it leaves. Section 3 presents the model. Section 4 tests it in the pharmaceutical sector, through India’s Section 3(d) and Section 84 and the experiences of Thailand and Brazil. Section 5 looks at the Article 31bis export mechanism and the limits of Article 66.2 reporting, and Section 6 at how WTO dispute settlement has marked out the boundaries of policy space under Articles 30, 70.8 and 73. Section 7 sets out a practical agenda for developing countries.
2. TRIPS as a Minimum-Standards Framework
TRIPS forms Annex 1C of the Marrakesh Agreement Establishing the World Trade Organization.7 Earlier conventions administered by the World Intellectual Property Organization (WIPO), such as the Paris Convention8 and the Berne Convention,9 relied largely on national treatment and did not require every state to cover the same subject matter. TRIPS went further and set mandatory minimum standards across seven categories of intellectual property.10
For patents, Members must protect inventions in all fields of technology, products and processes alike, for at least twenty years, so long as the claims are new, involve an inventive step and are capable of industrial application.11 Part III adds obligations on civil and administrative enforcement, provisional remedies and border measures.12 All of this stands behind the compulsory jurisdiction of the WTO dispute settlement system, which exposes a non-compliant state to binding reports and retaliatory trade measures.13
It would still be inaccurate to call TRIPS a uniform global code. It sets baseline standards; it does not create a single international patent. Patents remain territorial rights, created and administered under national law.14 The text also contains deliberate compromises that leave Members some room to choose, usually called ‘TRIPS flexibilities’.15
The basis for that discretion is Article 1.1, under which Members are free to decide how to implement the Agreement within their own legal systems. Articles 7 and 8 supply the substantive objectives. Article 7 says that the protection and enforcement of intellectual property rights should contribute to technological innovation and to the transfer and dissemination of technology, for the mutual advantage of producers and users and in a manner conducive to social and economic welfare. Article 8.1 allows Members to adopt measures necessary to protect public health and nutrition and to promote the public interest in sectors of vital socio-economic importance, provided those measures are consistent with the Agreement.16
How much legal weight Articles 7 and 8 carry has been disputed. Developed countries and commercial right holders have often treated them as introductory statements with no operative force. Yet Article 31(1) of the Vienna Convention on the Law of Treaties (VCLT) requires a treaty to be interpreted in good faith, according to the ordinary meaning of its terms in their context and in light of its object and purpose.17 WTO panels have repeatedly said that Articles 7 and 8 give important guidance when ambiguous provisions are interpreted and when domestic public-interest regulation is tested against the covered agreements.18
The substantive flexibilities are spread across several articles. Article 6 keeps national exhaustion regimes outside TRIPS dispute settlement, subject only to the non-discrimination rules in Articles 3 and 4, so a developing country may adopt international exhaustion and allow parallel imports of lower-priced genuine goods.19 Article 27.1 requires patents in all fields of technology but leaves ‘novelty’, ‘inventive step’ and ‘industrial applicability’ undefined, which gives national legislatures room to set demanding patentability thresholds that guard against secondary patenting and strategic evergreening.20 Article 30 permits limited exceptions to patent rights, provided they do not unreasonably conflict with normal exploitation of the patent or prejudice the legitimate interests of the patentee and third parties; it is the basis for regulatory review (‘Bolar’) exceptions that let generic manufacturers run clinical trials and make regulatory filings before the patent expires.21 Article 31 sets out the grounds for compulsory licences and public non-commercial use, and Article 40 confirms that Members may prevent and discipline anti-competitive licensing practices.
Listing these flexibilities is only a first step. Each is an exception bounded by strict conditions, not an open waiver. A compulsory licence under Article 31, for example, requires each application to be considered on its individual merits, documented efforts to obtain a voluntary licence on reasonable terms, limits on scope and duration, non-exclusivity, supply predominantly for the domestic market, and payment of adequate remuneration.22 The harder question is whether a state can assemble the administrative, legal and industrial capability to use what the text allows.
3. A Three-Pillar Framework
To connect treaty text to what actually happens to people, this article uses a three-part framework.
Legal policy space is the range of lawful discretion open to a government under multilateral agreements, regional treaties and domestic legislation; it defines what a state may lawfully do. Assessing it means looking at the treaty provisions, the 2001 Doha Declaration, bilateral free trade agreements (which often add TRIPS-plus restrictions), national patent statutes and WTO rulings. The relevant questions include how the statute defines a patentable invention, how it treats secondary claims, how wide the Article 30 exceptions are, what grounds exist for compulsory licensing under Article 31, and which exhaustion regime has been chosen under Article 6.23 Legal flexibility is the necessary opening. Without it, state action invites a formal challenge and possible trade retaliation.
Administrative state capacity covers the public bodies that turn statutory permissions into predictable, enforceable practice. Legal commentary often assumes that passing an Act completes the reform, but institutional economics suggests that statutory rights do little without administrative execution.24 Five components matter.
Patent registries come first. An office needs full-time examiners with scientific and technical training, digital access to prior-art databases, clear examination guidelines and some independence from applicants’ filing fees. Without these it drifts into rubber-stamping, granting weak patents that burden domestic enterprise. Courts matter just as much: specialised, impartial judges who can weigh technical evidence and deal with applications for preliminary injunctions without automatically shutting down legitimate generic production. Medicines regulators have to be able to carry out bioequivalence assessments, inspect manufacturing sites for compliance with Good Manufacturing Practice (GMP) and evaluate marketing applications without creating artificial patent-linkage barriers, and competition authorities must be able to define relevant geographic and product markets, spot restrictive licensing practices and apply remedial compulsory licences under Article 40. Then there is coordination between the ministries of trade, health, industry and finance. Policy incoherence is a persistent problem across the Global South, where trade officials often accept TRIPS-plus terms in bilateral negotiations without consulting health authorities or scientific bodies.25
Domestic productive capability is the country’s underlying scientific, manufacturing and commercial base, and it determines whether local actors can absorb and use the legal openings. A legal rule can remove an intellectual property barrier and an administrative body can issue a licence, but neither can synthesise an active ingredient, validate a formulation or run a distribution network. What is needed, first, is manufacturing plants that meet WHO-prequalified or other internationally recognised cGMP standards and can make good-quality generics at scale. It also takes people: scientists, chemical engineers and laboratory technicians who can read a patent disclosure, adapt a formula and troubleshoot commercial synthesis.26 Capital-intensive plants and bioequivalence trials call for affordable commercial finance, long-term credit and public support. And the products have to reach patients, which depends on centralised public tendering bodies able to buy generics in bulk, secure reliable quality control and supply clinics and vulnerable communities.
The framework’s diagnostic value lies in the fact that a break at any one point weakens the whole. A state with legal space and manufacturing capacity but weak administration is likely to see its patent office grant overlapping secondary patents that block local generic firms. A state with administrative competence and legal space but no domestic manufacturing will get little supply out of a compulsory licence, and will remain dependent on foreign exporters who may face legal and trade constraints of their own. The gap sits in a different place in each case, but the outcome is much the same.
4. Public Health in Practice: Compulsory Licensing and Domestic Patent Thresholds
Access to medicines is the clearest test of the framework. Conflict between patent exclusivity and public health led to the 2001 Doha Declaration on the TRIPS Agreement and Public Health.27 Adopted by consensus at the Fourth WTO Ministerial Conference, after international outcry over the price of antiretroviral therapy for HIV/AIDS, it remains an important political and legal milestone.
Paragraph 4 states that TRIPS ‘does not and should not prevent Members from taking measures to protect public health’ and affirms the right to ‘promote access to medicines for all’. Paragraph 5 confirms the sovereign flexibilities: each Member may grant compulsory licences, is free to decide the grounds on which they are granted, and may determine what amounts to a national emergency or extreme urgency, with public health crises expressly recognised as such.28
The Declaration’s legal status needs care. It was not an amendment to the treaty. It is an authoritative ministerial declaration of Members’ shared understanding of their rights under international law,29 and the conditions governing compulsory licences remained those of Article 31. Turning the principles of Doha into affordable healthcare took domestic legislative choices, supported by administrative and judicial institutions able to carry them through.
4.1 India’s Legislative Design: Section 3(d) and the Meaning of Efficacy
India shows how a developing country can build substantive safeguards within the limits of international trade law. After the landmark Ayyangar Committee Report of 1959, the Patents Act 1970 excluded product patents for pharmaceuticals, foods and agrochemicals and allowed only process patents, for terms of five to seven years.30 That model let a lively domestic generic industry grow. Indian firms became skilled at non-infringing process synthesis, pulled down the price of essential medicines worldwide and earned India the name ‘the pharmacy of the developing world’.31
As a developing country that did not grant pharmaceutical product patents, India was entitled under Article 65.4 of TRIPS to postpone product patent protection until 1 January 2005, provided it kept a ‘mailbox’ for receiving applications and granted exclusive marketing rights (EMRs) under Articles 70.8 and 70.9.32 When Parliament amended the patent law in 2005 to meet its treaty commitments, it knew well that originators often practise ‘evergreening’: obtaining secondary patents on small modifications, such as new salts, polymorphs, particle sizes or pure forms, to extend exclusivity beyond the expiry of the primary patent.33
To block that practice, Parliament amended Section 3(d) of the Patents Act 1970 through the Patents (Amendment) Act 2005.34 Section 3(d) excludes from patentability:
the mere discovery of a new form of a known substance which does not result in the enhancement of the known efficacy of that substance or the mere discovery of any new property or new use for a known substance or of the mere use of a known process, machine or apparatus unless such known process results in a new product or employs at least one new reactant.
The Explanation to Section 3(d) adds that salts, esters, ethers, polymorphs, metabolites, pure forms, particle sizes, isomers, complexes, combinations and other derivatives of a known substance are to be treated as the same substance unless they differ significantly in properties with regard to efficacy.35
The provision was tested in the well-known litigation over Novartis’s cancer medicine Glivec (imatinib mesylate). Novartis held a 1993 patent in several countries on the active molecule imatinib. In 1998 it filed a mailbox application in Chennai claiming the beta-crystalline form of imatinib mesylate, which it said had 30 percent higher bioavailability, lower hygroscopicity and better thermodynamic stability than the free-base compound.36
The Assistant Controller of Patents rejected the application under Section 3(d). Novartis challenged the decision and also mounted a constitutional challenge in the Madras High Court, arguing that Section 3(d) was arbitrarily vague under Article 14 of the Indian Constitution and breached India’s obligations under Article 27 of TRIPS.37 The High Court dismissed the challenge. It held that Indian courts had no jurisdiction to decide whether a domestic statute complied with a non-self-executing international treaty, and found Section 3(d) to be a legitimate provision aimed at safeguarding access to medicine.38
The dispute then reached the Supreme Court of India in Novartis AG v Union of India.39 The Court clarified what ‘efficacy’ means in Section 3(d): in the pharmaceutical context it is ‘therapeutic efficacy’, the capacity to cure or produce a healing effect in the human body.40 Physical properties such as better thermodynamic stability or lower moisture absorption concern storage and handling, not therapeutic value. Increased bioavailability might in principle affect therapeutic outcomes, but Novartis had offered no comparative clinical evidence that the beta-crystalline form was therapeutically more effective than the known parent substance. The application was therefore rejected.41
Read through the framework, Novartis looks like a case where all three conditions were met. India used the policy space left by Article 27.1, which leaves ‘invention’ undefined, to set its own standards of novelty and inventive step. It had an independent and technically competent judiciary, able to analyse detailed chemical and clinical evidence while resisting diplomatic pressure from outside. And its productive base was ready to respond: Indian generic manufacturers such as Cipla, Natco and Ranbaxy were already selling generic imatinib at roughly $175 a month, against a widely reported originator price of about $2,600, so affordable treatment remained available.42
4.2 Compulsory Licensing in Practice: Bayer v Natco
India’s administrative framework was tested again under Section 84 of the Patents Act 1970.43 Any interested person may apply for a compulsory licence three years after the grant of a patent, on three alternative grounds: that the reasonable requirements of the public have not been satisfied; that the patented invention is not available to the public at a reasonably affordable price; or that it is not worked in the territory of India.44
In March 2012 the Controller General of Patents granted India’s first post-TRIPS compulsory licence, to Natco Pharma, for Bayer’s kidney and liver cancer drug sorafenib tosylate (Nexavar).45 Bayer was selling a month’s course of Nexavar for roughly ₹280,000 (around $5,000); Natco undertook to supply a generic version at about ₹8,800 (roughly $160) a month, a reduction of 97 percent.46
The Controller’s order was carefully reasoned. It found that Bayer was reaching barely 2 percent of eligible cancer patients in India, so the reasonable requirements of the public were not met. On price, affordability had to be judged from the standpoint of the general public and patients’ purchasing power, not the patentee’s internal cost accounting. On local working under Section 84(1)(c), Bayer imported its entire supply and did no manufacturing in India, and mere importation did not satisfy the working requirement without adequate commercial justification.47 Natco received a non-exclusive licence for the remainder of the patent term, on payment of a 6 percent royalty (later raised to 7 percent by the appellate board) and with an obligation to supply the drug free to 600 indigent patients each year.48
Bayer appealed to the Intellectual Property Appellate Board (IPAB) and then to the Bombay High Court.49 In Bayer Corporation v Union of India the High Court upheld the licence.50 It ruled that the finding on affordability was enough on its own: where a life-sustaining medicine is priced beyond the reach of 98 percent of patients, the patentee has not met the statutory requirement of reasonably affordable access. The case shows that a working compulsory licensing system does not depend on administrative fiat. It needs open hearings, documented market data and rigorous judicial oversight.51
4.3 Thailand and Brazil
The cases of Thailand and Brazil show the importance of productive and procurement capability. They are, admittedly, instances in which flexibilities were used with some success; failures are less well documented, and a fuller test of the framework would look at them too. Between 2006 and 2008 the Thai Ministry of Public Health issued seven government-use decrees under Section 51 of the Patent Act B.E. 2522 (1979) and Article 31 of TRIPS.52 They covered two antiretroviral therapies (efavirenz and lopinavir/ritonavir), a cardiovascular anticoagulant (clopidogrel) and four cancer medicines (imatinib, letrozole, docetaxel and erlotinib).53
The public health results were notable, with wider access to second-line therapies across the public hospital network. But the legal decrees alone did not produce them. Thailand already had the Government Pharmaceutical Organization (GPO), a public enterprise under the Ministry of Public Health,54 whose facilities could formulate efavirenz locally and which kept supply arrangements for importing generic clopidogrel and cancer medicines from India while domestic production was being established. Thailand had also built a Universal Health Coverage Scheme overseen by the National Health Security Office (NHSO).55 The NHSO acted as a single public purchaser: it pooled demand, negotiated bulk contracts and distributed medicines through public clinics at no out-of-pocket cost to patients. The decrees were simply the administrative trigger that set an existing public manufacturing and procurement system in motion.
Brazil’s history makes a similar point, and shows that productive capability has to be built over time. Federal Law No 9,313 of 1996 guaranteed universal, free access to HIV/AIDS medication through the Unified Health System (SUS).56 To keep the programme fiscally viable, the government repeatedly used the possibility of compulsory licences under Article 68 of the Industrial Property Law (Law No 9,279 of 1996) as leverage in price negotiations with multinational patentees, and obtained price reductions of between 40 and 70 percent on drugs such as nelfinavir and lopinavir/ritonavir.57
When talks over Merck’s efavirenz broke down in 2007, President Luiz Inácio Lula da Silva signed Decree No 6,108 of 4 May 2007, declaring the drug to be of public interest and authorising a non-commercial government-use licence under Article 31 of TRIPS.58 The sequence that followed is instructive. Brazil could not yet formulate the drug at home, so in the first phase the Ministry of Health imported WHO-prequalified generic efavirenz from Indian manufacturers at $0.45 per tablet, compared with Merck’s price of $1.57, saving the public health budget more than $30 million a year.59
In the second phase the government gave its public pharmaceutical laboratory, Farmanguinhos (part of the Oswaldo Cruz Foundation, Fiocruz), the task of developing the drug domestically. The state invested substantial public funds to reverse-engineer the formulation, secure active ingredients and demonstrate clinical bioequivalence.60 Within a few years Farmanguinhos was producing generic efavirenz at home, and the entire manufacturing process was in public hands.61 Brazil’s experience confirms that a compulsory licence does not by itself create production capacity. What it provides is the legal window and the financial breathing room needed to carry out a sustained public industrial strategy.
5. Where the Multilateral Regime Falls Short: Article 31bis and Technology Transfer
Larger developing countries such as India, Thailand and Brazil have at times been able to mobilise administrative and industrial capacity to use the flexibilities. For smaller developing countries and least-developed countries (LDCs) without domestic manufacturing, the TRIPS framework poses serious obstacles.
5.1 Article 31bis
A major structural limit in the original Agreement was Article 31(f), under which any use authorised without the right holder’s consent must be authorised predominantly for the supply of the domestic market of the authorising Member.62 That left countries without pharmaceutical plants in an awkward position. An LDC facing a health crisis could lawfully issue a compulsory licence under its own law, yet no foreign generic manufacturer could use an ordinary compulsory licence in its own country to supply that demand, because the exports would not be ‘predominantly for the supply of its domestic market’.63
Paragraph 6 of the Doha Declaration told the TRIPS Council to find a solution.64 After lengthy negotiations the WTO General Council adopted the Decision of 30 August 2003 (the ‘Paragraph 6 Waiver’).65 The waiver was eventually converted into a treaty amendment, Article 31bis, which entered into force on 23 January 2017 after two-thirds of Members had deposited instruments of acceptance.66
Article 31bis waives the domestic-market limit in Article 31(f) for pharmaceutical exports to eligible importing Members. The procedure surrounding it, however, has made it close to unworkable commercially.67 The importing Member must notify the TRIPS Council of the products and quantities required and show that it has insufficient or no manufacturing capacity, and it must issue its own compulsory licence if the product is patented in its territory. A generic manufacturer in the exporting country must first try to negotiate a voluntary licence with the patentee and, failing that, apply for a special export compulsory licence under its own national law. That licence is limited strictly to the notified quantity, and the entire production run must be shipped to the designated importing country. The medicines must be distinguished by special packaging, colouring or shaping, with all the specifications posted on a public website before dispatch, and adequate remuneration must be paid in the exporting country, taking into account the economic value to the importing country.68
Given this complexity, it is not surprising that in more than two decades Article 31bis has been used only once in international trade. In 2007–2008 the Canadian generic firm Apotex used Canada’s implementing legislation, the Jean Chrétien Pledge to Africa, to supply an antiretroviral combination drug (Apo-TriAvir) to Rwanda.69 Even that transaction met heavy administrative friction. Roughly fourteen months passed between Rwanda’s notification to the WTO in July 2007 and the first consignment leaving Canada in September 2008, and nearly three years had gone by since Apotex first took steps to use the system.70 Apotex later described the regime as unworkable as it stood and said it was reluctant to use it again.71 Generic manufacturing depends on volume, predictable planning and economies of scale, and private firms cannot operate profitably if they must pass through a long, multi-step procedure to fill a small one-off order for a single market. The export system was designed mainly to prevent trade diversion, with little regard for commercial workability, and the result is a mechanism that exists on paper and is largely dormant in practice.
5.2 Article 66.2 and Technology Transfer
The distance between treaty text and domestic capability is just as visible in technology transfer. In the Uruguay Round, developing states accepted demanding intellectual property standards partly on the understanding that industrialised countries would encourage technology transfer and help build local productive capacity.72 The main provision reflecting that understanding is Article 66.2 of TRIPS, which states:
Developed country Members shall provide incentives to enterprises and institutions in their territories for the purpose of promoting and encouraging technology transfer to least-developed country Members in order to enable them to create a sound and viable technological base.
Article 66.2 is worded as a mandatory obligation: developed country Members ‘shall provide incentives’. In practice it has worked mainly as a reporting exercise.73 To address the lack of measurable progress, the TRIPS Council adopted a decision in February 2003 requiring developed countries to submit annual reports on how their domestic incentives promote technology transfer.74
The submissions reveal a clear pattern of non-compliance.75 Developed countries often report ordinary development aid, general student scholarships, environmental remediation projects or commercial trade missions, none of which involves transferring proprietary industrial know-how. Reported activities frequently include basic training seminars or business workshops held in developing countries, which transfer no proprietary processes and establish no local manufacturing. Almost none of the programmes offer concrete tax, financial or regulatory incentives for biotechnology or pharmaceutical companies to license proprietary technologies, share manufacturing formulas or enter joint production ventures in LDCs.76
Real technology transfer does not happen through patent disclosure alone. A patent document explains an inventive concept to a skilled technician; it rarely reveals the uncodified tacit know-how, precise reaction parameters and quality assurance protocols needed to run a factory efficiently.77 Unless policy addresses that tacit industrial knowledge, the system risks entrenching technological divides, with industrialised countries keeping proprietary know-how and manufacturing power while developing economies remain consumer markets.
6. WTO Dispute Settlement and the Limits of Policy Space
Developing countries have tried to build policy space through domestic statutes and court decisions, but these measures operate under the scrutiny of WTO dispute settlement. Rulings by panels and the Appellate Body have drawn the legal boundaries of TRIPS flexibilities, and have rejected attempts to stretch exceptions beyond the limits of the treaty.
6.1 The Regulatory Review Exception: Canada – Pharmaceutical Products
The limits of Article 30 were set in Canada – Patent Protection of Pharmaceutical Products (DS114).78 The European Communities challenged two provisions of the Canadian Patent Act: the regulatory review exception (Section 55.2(1)), which let generic companies use patented inventions without authorisation to generate clinical data for drug registration, and the stockpiling exception (Section 55.2(2)), which let generic manufacturers produce and store commercial quantities of medicines during the final six months of the patent term.79
The Panel set out a three-part test for Article 30: the exception must be ‘limited’; it must not ‘unreasonably conflict with a normal exploitation of the patent’; and it must not ‘unreasonably prejudice the legitimate interests of the patent owner, taking account of the legitimate interests of third parties’.80 It upheld Canada’s regulatory review exception, finding that it was confined to regulatory filings, allowed no commercial sales during the patent term and left normal exploitation intact. It struck down the stockpiling exception, holding that allowing commercial manufacture before expiry removed the patentee’s exclusive right to exclude others under Article 28.1 and unreasonably impaired normal commercial rights.81 The ruling established that Article 30 cannot serve as a broad public-interest exception: any domestic exception must be narrowly defined and administratively contained.
6.2 Mailbox Obligations: India – Patents (DS50)
The institutional obligations of the transition period were examined in India – Patent Protection for Pharmaceutical and Agricultural Chemical Products (DS50).82 The United States challenged India’s failure to establish a sound legal mechanism for receiving pharmaceutical mailbox applications and granting EMRs under Articles 70.8 and 70.9. After an amending ordinance lapsed in Parliament, India had tried to administer the mailbox through internal administrative instructions.83
The Appellate Body held that administrative circulars created legal uncertainty in a system where the Patents Act 1970 expressly prohibited product patents. Article 70.8, it ruled, obliges Members to provide a ‘sound legal basis’ that secures for patent applicants an enforceable right to claim priority from their filing date, protected from domestic legal challenge.84 The report established that administrative arrangements cannot substitute for binding statutory frameworks; states must implement treaty obligations through transparent, formal legislation.
6.3 A Note on Unadopted Reports: Saudi Arabia – IPR (DS567)
A final point concerns the legal status of WTO dispute reports. The panel report in Saudi Arabia – Measures Concerning the Protection of Intellectual Property Rights (DS567), circulated in June 2020, is a clear example.85 Qatar brought the dispute over Saudi Arabia’s failure to provide criminal enforcement procedures against the broadcast piracy network ‘beoutQ’, and the panel examined Saudi Arabia’s defence under the national security exception in Article 73(b)(iii) of TRIPS.86
The Panel’s analysis of whether Article 73 is objectively reviewable was detailed, but Saudi Arabia appealed the report in July 2020.87 Because the Appellate Body has lacked a quorum since December 2019, owing to the blocking of judicial appointments, the appeal was ‘appealed into the void’. Under Article 16.4 of the Dispute Settlement Understanding, a panel report that has been appealed cannot be adopted by the Dispute Settlement Body.88 The report therefore remains unadopted and has no formal legal status. Academic work and policy advice should keep unadopted panel reports distinct from binding rulings, since relying on them can introduce errors into domestic legal planning.
7. An Implementation Agenda
The three-pillar model shows that developing countries cannot widen access to knowledge or build domestic capacity merely by signing treaties or passing isolated statutory provisions. Effective reform needs a single strategy that addresses legal policy space, administrative state capacity and domestic productive capability together.
7.1 Legal Policy Space
Developing countries should review their intellectual property statutes systematically, and use the existing flexibilities fully, before entering bilateral or regional trade negotiations. Patentability criteria are the obvious place to start. Drawing on India’s Section 3(d), statutes can exclude new forms, new uses, polymorphs and combinations of known substances unless the applicant shows clinical proof of enhanced therapeutic efficacy. Regulatory review exceptions should be broad: clear Article 30 ‘Bolar’ provisions that let generic and biosimilar manufacturers use patented inventions for all the research, formulation and registration work needed to secure approval. An international exhaustion regime under Article 6 would allow lower-priced genuine medicines and goods to be imported in parallel. And compulsory licensing, whether under Article 31 or for public non-commercial use, needs predictable and straightforward procedures, with predetermined royalty formulas such as the UNDP/WHO Tiered Royalty Method so that ‘adequate remuneration’ does not become the subject of long disputes.89
7.2 Administrative Capacity
Statutory rights mean little without capable public institutions to administer them. Patent examination is the first candidate for investment: full-time, scientifically trained examiners, commercial prior-art databases, and open pre-grant and post-grant opposition. Pre-grant opposition lets domestic manufacturers and civil society challenge doubtful secondary applications before a patent issues, and so prevents improper monopolies. Medicines regulators need qualified scientists and certified bioequivalence laboratories, and their rules should avoid ‘patent linkage’, the practice of making marketing approval depend on the patent status of an originator drug, which turns health regulators into enforcement agents for private patentees. Competition authorities, for their part, should draw up dedicated guidelines on intellectual property licensing under Article 40 and keep watch for ‘pay-for-delay’ settlements, excessive pricing of essential inputs and abusive patent thickets that suppress follow-on domestic innovation. Coordination is the last piece: permanent bodies bringing together the ministries of health, industry, trade and science, and a rule that trade negotiators may not accept TRIPS-plus commitments, such as data exclusivity or patent term extensions, without a formal assessment of their public health and industrial impact.
7.3 Industrial and Productive Capability
Intellectual property policy has to be tied directly to national industrial and health strategy, which means building the practical ability to absorb, adapt and produce essential goods. Public research and formulation laboratories deserve support; Fiocruz in Brazil and the CSIR institutes in India show what bodies focused on chemical synthesis, reverse engineering and formulation development for priority domestic diseases can achieve. Smaller developing countries and LDCs cannot each sustain their own plants for every product, which is the case for regional pooled procurement. Organised through regional economic communities, and supported by regional regulatory bodies such as the African Medicines Agency (AMA), it could aggregate demand, negotiate lower prices and support designated regional manufacturing centres. At the WTO, developing countries should press beyond passive reporting under Article 66.2 and call for clear performance benchmarks linking trade concessions to real transfers of industrial know-how, specialised equipment and joint manufacturing ventures. At home, targeted tax policy, dedicated industrial parks, state financing and public procurement contracts can help generic manufacturers reach international cGMP standards.
8. Conclusion
Debates over TRIPS have too often dwelt on abstract legal terms and neglected administrative and industrial reality. The Agreement sets minimum standards and leaves a qualified, contested policy space; what that means for development turns on whether a country can pair its legal room for manoeuvre with working institutions and a productive base.
Statutory flexibilities do not enforce themselves. They need competent patent registries, independent courts, transparent health regulators and functioning manufacturing and procurement networks, and where administration is underfunded or industry is absent, the rights simply sit unused on the books. The framework offered here is a way of organising the evidence, not a tested causal model, and its illustrations come mainly from the pharmaceutical sector and from relatively large developing countries with established generic or public pharmaceutical industries. Whether the same logic holds in other sectors and in smaller economies is a question for further work. For the countries concerned, the way forward involves more than arguing over treaty clauses in Geneva or drafting model acts. It calls for long-term investment in administrative competence and productive capacity, and for international intellectual property policy to be anchored in industrial development and human health.
AI Use Disclosure
The author used ChatGPT (OpenAI) solely for grammar checking and language editing to improve the clarity, readability and presentation of the manuscript. The research, legal analysis, arguments, interpretations and conclusions are the author’s own.
Footnotes
- Marrakesh Agreement Establishing the World Trade Organization (opened for signature 15 April 1994, entered into force 1 January 1995) 1867 UNTS 154, Annex 1C (‘TRIPS Agreement’). ↩
- TRIPS Agreement (n 1) art 64; Understanding on Rules and Procedures Governing the Settlement of Disputes, Marrakesh Agreement Establishing the World Trade Organization, Annex 2, 1869 UNTS 401 (‘DSU’) arts 22–23. ↩
- Keith E Maskus, Intellectual Property Rights in the Global Economy (Institute for International Economics 2000) 143–158; Edwin Mansfield, ‘Intellectual Property Protection, Foreign Direct Investment, and Technology Transfer’ (1994) IFC Discussion Paper No 19, 1–22. ↩
- Peter Drahos and John Braithwaite, Information Feudalism: Who Owns the Knowledge Economy? (Earthscan 2002) 10–27, 134–149; Susan K Sell, Private Power, Public Law: The Globalization of Intellectual Property Rights (CUP 2003) 96–120. ↩
- Carlos M Correa, Intellectual Property Rights, the WTO and Developing Countries: The TRIPS Agreement and Policy Options (Zed Books 2000) 1–23. ↩
- Frederick M Abbott, ‘The TRIPS Agreement, Access to Medicines, and the WTO Doha Ministerial Conference’ (2002) 5(2) Journal of International Economic Law 469, 472–485. ↩
- Marrakesh Agreement Establishing the World Trade Organization (opened for signature 15 April 1994, entered into force 1 January 1995) 1867 UNTS 154, art II:2. ↩
- Paris Convention for the Protection of Industrial Property (as revised at Stockholm on 14 July 1967) 828 UNTS 305. ↩
- Berne Convention for the Protection of Literary and Artistic Works (as revised at Paris on 24 July 1971) 1161 UNTS 3. ↩
- TRIPS Agreement (n 1) arts 9–40 (covering copyright, trademarks, geographical indications, industrial designs, patents, integrated circuit layout-designs, and undisclosed information). ↩
- TRIPS Agreement (n 1) arts 27.1, 33. ↩
- TRIPS Agreement (n 1) Part III, arts 41–61. ↩
- DSU (n 2) art 22.3 (authorising cross-retaliation). ↩
- Antony Taubman, Hannu Wager and Jayashree Watal (eds), A Handbook on the WTO TRIPS Agreement (2nd edn, CUP 2020) 4–16. ↩
- Carlos M Correa, Trade Related Aspects of Intellectual Property Rights: A Commentary on the TRIPS Agreement (2nd edn, OUP 2020) 14–28. ↩
- TRIPS Agreement (n 1) arts 1.1, 7, 8.1. ↩
- Vienna Convention on the Law of Treaties (adopted 23 May 1969, entered into force 27 January 1980) 1155 UNTS 331 (VCLT) art 31(1). ↩
- WTO, Canada – Patent Protection of Pharmaceutical Products (Report of the Panel) WTO Doc WT/DS114/R (adopted 7 April 2000) paras 7.24–7.26; WTO, Australia – Certain Measures Concerning Trademarks, Geographical Indications and Other Plain Packaging Requirements (Reports of the Panel) WTO Doc WT/DS435/R, WT/DS441/R, WT/DS458/R, WT/DS467/R (adopted 29 June 2020) paras 7.2407–7.2411. ↩
- TRIPS Agreement (n 1) arts 3, 4, 6. ↩
- Correa, Commentary on TRIPS (n 15) 280–292. ↩
- WTO, Canada – Pharmaceutical Products (n 18) paras 7.45–7.58. ↩
- TRIPS Agreement (n 1) art 31(a)–(l). ↩
- Peter K Yu, ‘The Objectives and Principles of the TRIPS Agreement’ (2009) 46(4) Houston Law Review 979, 995–1018. ↩
- Douglass C North, Institutions, Institutional Change and Economic Performance (CUP 1990) 3–16; Dani Rodrik, One Economics, Many Recipes: Globalization, Institutions, and Economic Growth (Princeton University Press 2007) 153–194. ↩
- Carolyn Deere, The Implementation Game: The TRIPS Agreement and the Global Politics of Intellectual Property Reform in Developing Countries (OUP 2009) 112–148. ↩
- Wesley M Cohen and Daniel A Levinthal, ‘Absorptive Capacity: A New Perspective on Learning and Innovation’ (1990) 35(1) Administrative Science Quarterly 128, 131–139; Sanjaya Lall, ‘Indicators of the Relative Importance of IPRs in Developing Countries’ (2003) 32(9) Research Policy 1657, 1660–1672. ↩
- Declaration on the TRIPS Agreement and Public Health (adopted 14 November 2001) WTO Doc WT/MIN(01)/DEC/2 (Doha Declaration). ↩
- Doha Declaration (n 27) paras 4, 5(a)–(c). ↩
- James Thuo Gathii, ‘The Legal Status of the Doha Declaration on TRIPS and Public Health Under the Vienna Convention on the Law of Treaties’ (2002) 15(2) Harvard Journal of Law & Technology 291, 298–315. ↩
- Patents Act 1970 (India) s 5 (repealed by the Patents (Amendment) Act 2005). ↩
- Justice N Rajagopala Ayyangar, Report on the Revision of the Patents Law (Government of India 1959) 21–48; Sudip Chaudhuri, The WTO and India’s Pharmaceuticals Industry: Patent Protection, TRIPS, and Developing Countries (OUP 2005) 35–68. ↩
- TRIPS Agreement (n 1) arts 65.4, 70.8, 70.9. ↩
- Carlos M Correa, ‘Integrating Public Health Concerns into Patent Legislation in Developing Countries’ (South Centre 2000) 31–42. ↩
- Patents Act 1970 (India), as amended by the Patents (Amendment) Act 2005 (Act 15 of 2005) s 3(d). ↩
- Patents Act 1970 (India) s 3(d), Explanation. ↩
- Novartis AG v Union of India (2013) 6 SCC 1, paras 6–18. ↩
- Novartis AG v Union of India [2007] 4 MLJ 1153 (Mad HC). ↩
- Novartis AG (Mad HC) (n 37) paras 16–22. ↩
- Novartis AG v Union of India (2013) 6 SCC 1. ↩
- Novartis AG (SC) (n 39) paras 88–91, 157. ↩
- Novartis AG (SC) (n 39) paras 158–160. ↩
- Shamnad Basheer and T Prashant Reddy, ‘The “Efficacy” of Indian Patent Law: Ironing out the Creases in Section 3(d)’ (2008) 5(2) SCRIPTed 232; ‘Indian Court’s Novartis Ruling Keeps Door to Cheap Drugs Open’ SciDev.Net (2 April 2013). ↩
- Patents Act 1970 (India) s 84. ↩
- Patents Act 1970 (India) s 84(1)(a)–(c). ↩
- Natco Pharma Ltd v Bayer Corporation (Compulsory Licence Application No 1 of 2011, Controller General of Patents, Mumbai, 9 March 2012). ↩
- Natco v Bayer (n 45) paras 12–15, 41. ↩
- Natco v Bayer (n 45) paras 42–48. ↩
- Natco v Bayer (n 45) paras 52–54. ↩
- Bayer Corporation v Union of India (IPAB, OA/35/2012/PT/MUM, 4 March 2013). ↩
- Bayer Corporation v Union of India (2014) 60 PTC 277 (Bom HC). ↩
- Bayer Corporation v Union of India (IPAB) (n 49); Bayer Corporation v Union of India (Bom HC) (n 50); Abhinav Gupta and Aqa Raza, ‘Patent Law and Compulsory Licensing: Indian Perspective’ (2023) 29(1) Journal of Intellectual Property Rights 5. ↩
- Patent Act B.E. 2522 (1979) (Thailand) s 51; TRIPS Agreement (n 1) art 31. ↩
- Jakkrit Kuanpoth, ‘Compulsory Licences: Law and Practice in Thailand’ in Reto M Hilty and Kung-Chung Liu (eds), Compulsory Licensing: Practical Experiences and Ways Forward (Springer 2015) 61, 64–75. ↩
- Kuanpoth (n 53) 68–71. ↩
- Viroj Tangcharoensathien and others, ‘Health Systems Development in Thailand: A Solid Platform for Successful Implementation of Universal Health Coverage’ (2018) 391(10126) The Lancet 1205, 1208–1214. ↩
- Federal Law No 9,313 of 13 November 1996 (Brazil) (guaranteeing free distribution of ARVs through the Unified Health System (SUS)). ↩
- Industrial Property Law, Law No 9,279 of 14 May 1996 (Brazil) art 68; Jane Galvão, ‘Access to Antiretroviral Drugs in Brazil’ (2002) 360(9348) The Lancet 1862, 1863–1865. ↩
- Decree No 6,108 of 4 May 2007 (Brazil) Diário Oficial da União (5 May 2007). ↩
- WHO, WIPO and WTO, Promoting Access to Medical Technologies and Innovation: Intersections between Public Health, Intellectual Property and Trade (2nd edn, WHO 2020) 184–185. ↩
- Maurice Cassier and Marilena Correa, ‘Scaling Up and Reverse Engineering: Acquisition of Industrial Knowledge by Copying Drugs in Brazil’ (working paper, 2008) HAL halshs-02024011. ↩
- Cassier and Correa (n 60). ↩
- TRIPS Agreement (n 1) art 31(f). ↩
- Abbott, ‘The TRIPS Agreement, Access to Medicines’ (n 6) 480–484. ↩
- Doha Declaration (n 27) para 6. ↩
- Decision of the General Council, Implementation of Paragraph 6 of the Doha Declaration on the TRIPS Agreement and Public Health, WTO Doc WT/L/540 and Corr 1 (1 September 2003). ↩
- Protocol Amending the TRIPS Agreement (done 6 December 2005, entered into force 23 January 2017) WTO Doc WT/L/641. ↩
- Carlos M Correa, ‘Will the Amendment to the TRIPS Agreement Enhance Access to Medicines?’ (South Centre Policy Brief No 57, January 2019). ↩
- TRIPS Agreement (n 1) art 31bis; General Council Decision of 30 August 2003 (n 65) paras 2(a)–(c). ↩
- WTO Council for TRIPS, ‘Notification under Paragraph 2(a) of the Decision of 30 August 2003: Rwanda’ (19 July 2007) WTO Doc IP/N/9/RWA/1; Patent Act (RSC 1985, c P-4) (Canada) ss 21.01–21.2 (enacting Canada’s Access to Medicines Regime (CAMR)). ↩
- Jillian C Cohen-Kohler, Laura C Esmail and Andre Perez Cosio, ‘Canada’s Implementation of the Paragraph 6 Decision: Is It Sustainable Public Policy?’ (2007) 3 Globalization and Health 12; Laura C Esmail and Jillian Kohler, ‘The Politics behind the Implementation of the WTO Paragraph 6 Decision in Canada to Increase Global Drug Access’ (2012) 8 Globalization and Health 7. ↩
- Ashley Weber and Lisa Mills, ‘A One-Time-Only Combination: Emergency Medicine Exports under Canada’s Access to Medicines Regime’ (2010) 12(1) Health and Human Rights. ↩
- Jayashree Watal, Intellectual Property Rights in the WTO and Developing Countries (Kluwer Law International 2001) 23–42. ↩
- Suerie Moon, ‘Does TRIPS Art 66.2 Encourage Technology Transfer to LDCs? An Analysis of Country Submissions to the TRIPS Council (1999–2007)’ (UNCTAD-ICTSD Policy Brief No 2, December 2008). ↩
- Decision of the Council for TRIPS, Implementation of Article 66.2 of the TRIPS Agreement, WTO Doc IP/C/28 (adopted 19 February 2003). ↩
- Moon (n 73); Jessyca van Weelde, Xiaoping Wu, Ting-Wei (Alex) Chiang and Bassam Peter Khazin, ‘Reflection on the Implementation of Decision on Implementation of Article 66.2 of the TRIPS Agreement: Incentive for Technology Transfer to Least-Developed Countries’ (WTO Staff Working Paper ERSD-2023-12, 13 December 2023). ↩
- Moon (n 73); van Weelde and others (n 75). ↩
- Richard R Nelson and Sidney G Winter, An Evolutionary Theory of Economic Change (Harvard University Press 1982) 72–95. ↩
- WTO, Canada – Patent Protection of Pharmaceutical Products (Report of the Panel) WTO Doc WT/DS114/R (adopted 7 April 2000). ↩
- Patent Act (RSC 1985, c P-4) (Canada) s 55.2(1), (2). ↩
- WTO, Canada – Pharmaceutical Products (n 78) paras 7.20–7.22. ↩
- WTO, Canada – Pharmaceutical Products (n 78) paras 7.34–7.38. ↩
- WTO, India – Patent Protection for Pharmaceutical and Agricultural Chemical Products (Report of the Appellate Body) WTO Doc WT/DS50/AB/R (adopted 16 January 1998). ↩
- WTO, India – Patents (AB) (n 82) paras 28–34. ↩
- WTO, India – Patents (AB) (n 82) paras 58, 66–71. ↩
- WTO, Saudi Arabia – Measures Concerning the Protection of Intellectual Property Rights (Report of the Panel) WTO Doc WT/DS567/R (circulated 16 June 2020) [unadopted]. ↩
- WTO, Saudi Arabia – IPR (n 85) paras 7.234–7.294. ↩
- WTO, Saudi Arabia – Measures Concerning the Protection of Intellectual Property Rights – Notification of an Appeal by Saudi Arabia, WTO Doc WT/DS567/7 (30 July 2020) (communication dated 28 July 2020). ↩
- DSU (n 2) art 16.4. ↩
- UNDP and WHO, Remuneration Guidelines for Non-Voluntary Use of a Patent on Health Technologies (WHO/TCM/2005.1, 2005) 12–28. ↩
Article information and declarations
- Article history
- Received 11 November 2026 · Accepted 12 November 2026 · Published online 12 November 2026
- Review
- Editorial review by the Editor-in-Chief, including originality, citation and copyright checks. Handling editor: Shivanshu K. Srivastava, Editor-in-Chief.
- Conflict of interest
- The author(s) declare no conflict of interest.
- Funding
- The author(s) received no specific funding for this work.
- Originality
- Checked for similarity and citation accuracy before publication. The author(s) warrant that the work is original and not published elsewhere.
- Licence
- © The author(s). Open access under CC BY 4.0.
- Corrections
- Any correction or retraction will be published as a linked notice on this page.
How to cite (OSCOLA): Anuranj R, 'TRIPS Flexibilities and Institutional Capacity: Rethinking Intellectual Property and Development in Developing Countries' (2026) Lexfolio Journal of Law, Policy and Social Sciences
How to cite (Bluebook): Anuranj R, TRIPS Flexibilities and Institutional Capacity: Rethinking Intellectual Property and Development in Developing Countries, Lexfolio J.L. Pol’y & Soc. Sci. (2026)
© The author(s). Published by Lexfolio under the Creative Commons Attribution 4.0 International (CC BY 4.0) licence. Opinions are the author’s own. Submit your paper to LJLPS.